Margaret Billingsley

Email: mmbilli [at] mit . edu

Layer-by Layer Nanoparticles for Combination Therapy in Minimal Residual Disease

After receiving initial therapeutic interventions, over 85% of high grade serous ovarian cancer patients will relapse with incurable disease. These relapses are due to minimal residual disease (MRD) – the persistence of small populations of chemoresistant cancer cells that remain after these frontline treatments. My work aims to develop LbL-NPs for the targeted, combined delivery of small molecules and proteins to create more effective immunotherapies for MRD in ovarian cancer.